In agreement with these findings, JMJD2B silencing leads to an enhancement in the DNA-damage driven induction of the p53 targets p21 and PIG3. Functionally, we show that exogenous expression of JMJD2B significantly enhances the ability of human colon cancer cells to grow in vivo in a p53-dependent manner, whereas genetic inhibition of JMJD2B significantly delays in vivo tumor growth. Here, TP53 is linked to malignant colon neoplasm.